Investment research report – “Addressing unmet heart health needs” – released today

2nd June 2022

TAG Investment Bankers is pleased to announce today the publication of a research report which covers Cardiol Therapeutics Inc. (NASDAQ: CRDL).  Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular disease (“CVD”). The company’s lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is being clinically developed for use in cardiovascular medicine. CardiolRx is currently being evaluated in a Phase II/III multi-national, randomized, double-blind, placebo-controlled study (the “LANCER” trial). 

AG Investment Bankers argues that Cardiol Therapeutics appears well placed to address important unmet medical needs across multiple cardiovascular areas, including acute myocarditis, recurrent pericarditis, and chronic heart failure.  The company’s focus on cannabidiol as an anti-inflammatory and anti-fibrotic therapy in our view implies significant revenue generation potential.  CardiolRx’s™ opportunity to be a “game changer” in heart health appears not to be reflected in its current stock market valuation.  Today’s report argues for an US$8.00 fair value per share for the company’s NASDAQ listing, based on arguably conservative assumptions.


Chris Wickham
Chief Marketing Officer
TAG Investment Bankers Ltd 
Tel: +4477 6465 5390

Please refer to the research report’s disclaimer which is copied in full on page 2 of this Press Release.

Please enable JavaScript in your browser to complete this form.


Cardiol Therapeutics paid TAG Investment Bankers analyst Chris Wickham to produce this report.  This report has been published by TAG Investment Bankers Ltd. TAG Investment Bankers Ltd do not offer personal advice, and the information referred to on our sites is not suitable for all investors. You confirm that you are a person falling within the following categories of an appropriately qualified investor and are therefore exempt from the general restriction on thecommunication of invitations or inducements to engage in investment activity on the grounds that you are, either; a high net worth individual, a sophisticated investor, an Investment Professional or a representative of a high net worth company, trust, partner- ship or association. If you are unsure whether an investment is suitable for your circumstances, we strongly encourage you to consult an FCA/SEC or other Financial Regulator in your country of residence – authorized Independent Financial Adviser before committing to any form of investment. All information and numbers are subject to change without notice. Any return on investment stated is for discussion purposes only and is based on a best-efforts basis. Under no circumstances whatsoever does it represent a fair and accurate view of actual results. Please be advised that it will change or might change in the future and that under no circumstances whatsoever can we or any of our associates, employees or partners be held responsible if the forecasted results are not met.  Neither Chris Wickham nor TAG Investment Bankers is currently a registered holder of Cardiol Therapeutics shares.